Zydus Cadila has received the final approval from the USFDA to market Desoximetasone Ointment USP, 0.25% . Desoximetasone Ointment is used in relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The drug will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.
 
The group also received the final approval from the USFDA to market Labetalol Hydrochloride Tablets USP in the strengths of 100 mg, 200 mg, and 300 mg. Labetalol Hydrochloride Tablets are used to treat high blood pressure (hypertension). The drug will be manufactured at the group's formulations manufacturing facility at the Pharma SEZ, Ahmedabad.

The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 3.3, or 0.68%, to trade at Rs 489.85. The total volume of shares traded was 7,532 at the BSE (9.43 a.m., Thursday).